

Please see the coverage summary for October 2025 Codes as below:

**Not covered experimental and investigational for Commercial and ASO Plans:**

A2036	Cohealyx collagen dermal matrix, per square centimeter
A2037	G4derm plus, per milliliter
A2038	Marigen pacto, per square centimeter
A2039	Innovamatrix fd, per square centimeter
C1740	Leadless electrode, transmitter, battery (all implantable), for sequential left ventricular pacing
J3403	Revakinagene taroretcel-lwey, per implant
Q4383	Axolotl graft ultra, per square centimeter
Q4384	Axolotl dualgraft ultra, per square centimeter
Q4385	Apollo ft, per square centimeter
Q4386	Acesso trifaca, per square centimeter
Q4387	Neothelium ft, per square centimeter
Q4388	Neothelium 4l, per square centimeter
Q4389	Neothelium 4l+, per square centimeter
Q4390	Ascendion, per square centimeter
Q4391	Amnioplast double, per square centimeter
Q4392	Grafix duo, per square centimeter
Q4393	Surgraft ac, per square centimeter
Q4394	Surgraft aca, per square centimeter
Q4395	Acelagraft, per square centimeter
Q4396	Natalin, per square centimeter
Q4397	Summit aaa, per square centimeter
0577U	Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring mode, reported as likelihood of malignancy
0579U	Nephrology (diabetic chronic kidney disease), enzyme-linked immunosorbent assay (ELISA) of apolipoprotein A4 (APOA4), CD5 antigen-like (CD5L) combined with estimated glomerular filtration rate (GFR), age, plasma, algorithm reported as a risk score for kidney function decline
0580U	Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG
0581U	Transplantation medicine, antibody to non-human leukocyte antigens (non-HLA), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported
0584U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative
0587U	Therapeutic drug monitoring, 60-150 drugs and metabolites, urine, saliva, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects
0589U	Perfluoroalkyl substances (PFAS) (eg, perfluoroctanoic acid, perfluorooctane sulfonic acid), 24 PFAS compounds by high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative
0591U	Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer

0594U	Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis
0596U	Neurology (Alzheimer disease), plasma, 3 distinct isoform-specific peptides (APOE2, APOE3, and APOE4) by liquid chromatography with tandem mass spectrometry (LC-MS/MS), reported as an APOE prototype
0598U	Gastroenterology (irritable bowel syndrome), IgG antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels
0599U	Oncology (pancreatic cancer), multiplex immunoassay of ICAM1, TIMP1, CTSD, THBS1, and CA 19-9, serum, diagnostic algorithm reported as positive or negative

**Not covered per benefit for Commercial and ASO Plans:**

E0150	Combination wheeled walker with seat and transport chair, folding, adjustable or fixed height
-------	---

**Covered when prior authorized for MGB ACO Plans:**

J9011	Injection, datopotamab deruxtecan-dlnk, 1 mg
J0614	Injection, treosulfan, 50 mg
J1612	Injection, glucagon (gvoke), 0.01 mg
C9305	Injection, nipocalimab-aahu, 3 mg
J1809	Injection, fosdenopterin, 0.1 mg
J3402	Injection, remestemcel-l-rknd, per therapeutic dose

**Covered when prior authorized for Commercial and ASO Plans:**

C9306	Injection, telisotuzumab vedotin-tllv, 1 mg
C8006	Insertion of pleural-peritoneal shunt with intercostal pump chamber, including imaging, injection(s) of contrast with radiological supervision and interpretation, when performed
J0614	Injection, treosulfan, 50 mg
J1612	Injection, glucagon (gvoke), 0.01 mg
J1809	Injection, fosdenopterin, 0.1 mg
J9011	Injection, datopotamab deruxtecan-dlnk, 1 mg
J3402	Injection, remestemcel-l-rknd, per therapeutic dose
J7173	Injection, concizumab-mtc1, 0.5 mg
J7174	Injection, fitusiran, 0.04 mg
L1007	Scoliosis orthosis, sagittal-coronal control provided by a rigid lateral frame, extends from axilla, to trochanter, includes all accessory pads, straps, and interface, custom fabricated
L5657	Addition to lower extremity prosthesis, manual/automated adjustable air, fluid, gel or equal socket insert for limb volume management, any materials
L6034	Partial hand, finger, and thumb prosthesis without prosthetic digit(s)/thumb, amputation at distal to metacarpal joint, including flexible or non-flexible interface, molded to patient model, for use without external power and/or passive prosthetic digit/thumb, not including inserts described by L6692
L6035	Single prosthetic digit, mechanical, can include metacarpophalangeal (mcp), proximal interphalangeal (pip), and/or distal interphalangeal (dip) joint(s), with or without locking mechanism, can include flexion or extension assist, any material, attachment, initial issue or replacement

L6036	Prosthetic thumb, mechanical, can include metacarpophalangeal (mcp), interphalangeal (ip) joint(s), with or without locking mechanism, can include flexion or extension assist, any material, attachment, initial issue or replacement
L6038	Addition to single prosthetic digit or thumb, mechanical, attachment, multiaxial and/or internal/external rotation/abduction/adduction mechanism, with or without locking feature, any material
L6039	Passive prosthetic digit or thumb prosthesis not including hand restoration partial hand, full or partial, custom made, any material, initial or replacement, per single passive prosthetic digit or thumb

**Covered when prior authorized via eviCore for Commercial and ASO Plans:**

0575U	Transplantation medicine (liver allograft rejection), miRNA gene expression profiling by RT-PCR of 4 genes (miR-122, miR-885, miR-23a housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection
0576U	Transplantation medicine (liver allograft rejection), quantitative donor-derived cell-free DNA (cfDNA) by whole genome next-generation sequencing, plasma and mRNA gene expression profiling by multiplex real-time PCR of 56 genes, whole blood, combined algorithm reported as a rejection risk score
0578U	Oncology (cutaneous melanoma), RNA, gene expression profiling by real-time qPCR of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence
0582U	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported
0583U	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported with proband results (List separately in addition to code for primary procedure)
0585U	Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free DNA (cfDNA) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, and microsatellite instability, report shows identified mutations, including variants with clinical actionability
0586U	Oncology, mRNA, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), RNA expression analysis, formalin-fixed paraffin-embedded (FFPE) tissue, quantitative, reported as log2 ratio per gene
0592U	Oncology (hematolymphoid neoplasms), DNA, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements, utilizing formalin-fixed paraffin-embedded (FFPE) tumor tissue, results report clinically significant variant(s)
0597U	Oncology (breast), RNA expression profiling of 329 genes by targeted next-generation sequencing and 20 proteins by multiplex immunofluorescence, formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic analyses to determine tumor-recurrence risk score

**Covered with no prior authorization required for Commercial and ASO Plans:**

A4288	Valve for breast pump, replacement
-------	------------------------------------

A9612	Injection, fluorescein, 1 mg
C1741	Anchor/screw for bone fixation, absorbable (implantable)
C1742	Pressure monitoring system, compartmental intramuscular (implantable), continuous, including all components (e.g., introducer, sensor), excludes mobile (wireless) software application
E0658	Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full arms and chest
E0659	Segmental pneumatic appliance for use with pneumatic compressor, integrated, head, neck and chest
J0163	Injection, epinephrine in sodium chloride (endo), 0.1 mg
J0164	Injection, epinephrine in sodium chloride (baxter), 0.1 mg
J0462	Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg
J0458	Injection, aztreonam/avibactam, 7.5 mg/2.5 mg (10 mg)
J0525	Injection, cefotetan disodium, 10 mg
J0582	Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
J0668	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
J0675	Injection, carboprost tromethamine, 0.1 mg
J0681	Injection, ceftobiprole medocaril sodium, 3 mg
J0738	Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0759	Injection, clevidipine butyrate, 1 mg
J1370	Injection, esomeprazole sodium, 1 mg
J1807	Injection, ethacrynatate sodium, 1 mg
J1834	Injection, isoniazid, 1 mg
J2151	Injection, mannitol, 250 mg
J2291	Injection, nafcillin sodium (baxter), 20 mg
J3290	Injection, tranexamic acid, 5 mg
M0235	Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose
M0236	Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose
M0237	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
M0238	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose

Q0235	Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
Q0237	Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
0588U	Infectious disease (bacterial or viral), 32 genes (29 informative and 3 housekeeping), immune response mRNA, gene expression profiling by split-well multiplex reverse transcription loop-mediated isothermal amplification (RT-LAMP), whole blood, reported as continuous risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days
0590U	Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism
0593U	Infectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected
0595U	Infectious disease (tropical fever pathogens), vector-borne and zoonotic pathogens, including 2 viruses (Chikungunya virus and Dengue virus serotypes 1, 2, 3, and 4), 1 bacterium (Leptospira species), and 1 parasite with species differentiation (Plasmodium species, Plasmodium falciparum, and Plasmodium vivax/ovale), real-time RT-PCR, whole blood, each pathogen reported as detected or not detected

**Covered with no prior authorization required for MGB ACO Plans:**

J0163	Injection, epinephrine in sodium chloride (endo), 0.1 mg
J0164	Injection, epinephrine in sodium chloride (baxter), 0.1 mg
J0462	Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg
J0525	Injection, cefotetan disodium, 10 mg
J0582	Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
J0675	Injection, carboprost tromethamine, 0.1 mg
J0668	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
J0759	Injection, clevidipine butyrate, 1 mg
J1370	Injection, esomeprazole sodium, 1 mg
J1807	Injection, ethacrynatate sodium, 1 mg
J1834	Injection, isoniazid, 1 mg
J2151	Injection, mannitol, 250 mg
J2291	Injection, nafcillin sodium (baxter), 20 mg
J3290	Injection, tranexamic acid, 5 mg
M0235	Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose
M0236	Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose

M0237	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
M0238	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
Q0235	Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
Q0237	Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
Q5155	Injection, afibercept-jbvf (yesafili), biosimilar, 1 mg

**Not covered experimental and investigational for Medicare Advantage Plans:**

C1740	Leadless electrode, transmitter, battery (all implantable), for sequential left ventricular pacing
J3403	Revakinagene taroretcel-lwey, per implant
0577U	Oncology (ovarian), serum, analysis of 39 glycoproteins by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in multiple reaction monitoring mode, reported as likelihood of malignancy
0579U	Nephrology (diabetic chronic kidney disease), enzyme-linked immunosorbent assay (ELISA) of apolipoprotein A4 (APOA4), CD5 antigen-like (CD5L) combined with estimated glomerular filtration rate (GFR), age, plasma, algorithm reported as a risk score for kidney function decline
0580U	Borrelia burgdorferi, antibody detection of 24 recombinant protein groups, by immunoassay, IgG
0581U	Transplantation medicine, antibody to non-human leukocyte antigens (non-HLA), blood specimen, flow cytometry, single-antigen bead technology, 39 targets, individual positive antibodies reported
0584U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative
0587U	Therapeutic drug monitoring, 60-150 drugs and metabolites, urine, saliva, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), specimen validity, and algorithmic analyses for presence or absence of drug or metabolite, risk score predicted for adverse drug effects
0589U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 24 PFAS compounds by high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative
0591U	Oncology (prostate cancer), biochemical analysis of 3 proteins (total PSA, free PSA, and HE4), plasma, serum, prognostic algorithm incorporating 3 proteins and digital rectal examination, results reported as a probability score for clinically significant prostate cancer
0594U	Infectious disease (sepsis), semiquantitative measurement of pancreatic stone protein concentration, whole blood, reported as risk of sepsis
0596U	Neurology (Alzheimer disease), plasma, 3 distinct isoform-specific peptides (APOE2, APOE3, and APOE4) by liquid chromatography with tandem mass spectrometry (LC-MS/MS), reported as an APOE prototype
0598U	Gastroenterology (irritable bowel syndrome), IgG antibodies to 18 food items by microarray-based immunoassay, whole blood or serum, report as elevated (positive) or normal (negative) antibody levels
0599U	Oncology (pancreatic cancer), multiplex immunoassay of ICAM1, TIMP1, CTSD, THBS1, and CA 19-9, serum, diagnostic algorithm reported as positive or negative

**Non-Covered for Medicare Advantage Plans:**

E0150	Combination wheeled walker with seat and transport chair, folding, adjustable or fixed height
-------	---

**Covered with prior authorization required for Medicare Advantage Plans:**

A2036	Cohealyx Collagen Dermal Matrix, per sq cm
A2037	G4Derm Plus, per ml
A2038	MariGen Pacto, per sq cm
A2039	InnovaMatrix FD, per sq cm
C8006	Insertion of pleural-peritoneal shunt with intercostal pump chamber, including imaging, injection(s) of contrast with radiological supervision and interpretation, when performed
C9305	Injection, nipocalimab-aahu, 3 mg
C9306	Injection, telisotuzumab vedotin-tllv, 1 mg
J0614	Injection, treosulfan, 50 mg
J1809	Injection, fosdenopterin, 0.1 mg
J3402	Injection, remestemcel-l-rknd, per therapeutic dose
J7173	Injection, concizumab-mtci, 0.5 mg
J7174	Injection, fitusiran, 0.04 mg
J9011	Injection, datopotamab deruxtecan-dlnk, 1 mg
L1007	Scoliosis orthosis (SO), sagittal-coronal control provided by a rigid lateral frame, extends from axilla, to trochanter, includes all accessory pads, straps, and interface, custom fabricated
L5657	Addition to lower extremity prosthesis, manual/automated adjustable air, fluid, gel or equal socket insert for limb volume management, any materials
L6034	Partial hand, finger, and thumb prosthesis without prosthetic digit(s)/thumb, amputation at transmetacarpal level, including flexible or non-flexible interface, molded to patient model, for use without external power and/or passive prosthetic digit/thumb, not including inserts described by L6692
L6035	Single prosthetic digit, mechanical, can include metacarpophalangeal (MCP), proximal interphalangeal (PIP), and/or distal interphalangeal (DIP) joint(s), with or without locking mechanism, can include flexion or extension assist, any material, attachment, initial issue or replacement
L6036	Prosthetic thumb, mechanical, can include metacarpophalangeal (MCP), interphalangeal (IP) joint(s), with or without locking mechanism, can include flexion or extension assist, any material, attachment, initial issue or replacement
L6038	Addition to single prosthetic digit or thumb, mechanical, attachment, multiaxial and/or internal/external rotation/abduction/adduction mechanism, with or without locking feature, any material
L6039	Passive prosthetic digit or thumb prosthesis not including hand restoration partial hand, full or partial, custom made, any material, initial or replacement, per single passive prosthetic digit or thumb
Q5155	Injection, afibbercept-jbvf (yesafili), biosimilar, 1 mg
Q5157	Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
Q5158	Injection, denosumab-bnht (bomynta/conexxence), biosimilar, 1 mg
Q5159	Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg
0575U	Transplantation medicine (liver allograft rejection), miRNA gene expression profiling by RT-PCR of 4 genes (miR-122, miR-885, miR-23a housekeeping, spike-in control), serum, algorithm reported as risk of liver allograft rejection

0576U	Transplantation medicine (liver allograft rejection), quantitative donor-derived cell-free DNA (cfDNA) by whole genome next-generation sequencing, plasma and mRNA gene expression profiling by multiplex real-time PCR of 56 genes, whole blood, combined algorithm reported as a rejection risk score
0578U	Oncology (cutaneous melanoma), RNA, gene expression profiling by real-time qPCR of 10 genes (8 content and 2 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reports a binary result, either low-risk or high-risk for sentinel lymph node metastasis and recurrence
0582U	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported
0583U	Rare diseases (constitutional disease/hereditary disorders), rapid whole genome comparator DNA sequencing for single-nucleotide variants, insertions/deletions, copy number variations, blood, saliva, tissue sample, variants reported with proband results (List separately in addition to code for primary procedure)
0585U	Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free DNA (cfDNA) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, and microsatellite instability, report shows identified mutations, including variants with clinical actionability
0586U	Oncology, mRNA, gene expression profiling of 216 genes (204 targeted and 12 housekeeping genes), RNA expression analysis, formalin-fixed paraffin-embedded (FFPE) tissue, quantitative, reported as log2 ratio per gene
0592U	Oncology (hematolymphoid neoplasms), DNA, targeted genomic sequence of 417 genes, interrogation for gene fusions, translocations, rearrangements, utilizing formalin-fixed paraffin-embedded (FFPE) tumor tissue, results report clinically significant variant(s)
0597U	Oncology (breast), RNA expression profiling of 329 genes by targeted next-generation sequencing and 20 proteins by multiplex immunofluorescence, formalin-fixed paraffin-embedded (FFPE) tissue, algorithmic analyses to determine tumor-recurrence risk score

**Covered with no prior authorization required for Medicare Advantage Plans:**

A4288	Valve for breast pump, replacement
A9612	Injection, fluorescein, 1 mg
A9616	Gallium Ga-68 gozetotide (Gozellix), diagnostic, 1 mCi
C1741	Anchor/screw for bone fixation, absorbable (implantable)
C1742	Pressure monitoring system, compartmental intramuscular (implantable), continuous, including all components (e.g., introducer, sensor), excludes mobile (wireless) software application
E0658	Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full arms and chest
E0659	Segmental pneumatic appliance for use with pneumatic compressor, integrated, head, neck and chest
J0163	Injection, epinephrine in sodium chloride (endo), 0.1 mg
J0164	Injection, epinephrine in sodium chloride (baxter), 0.1 mg
J0462	Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg
J0458	Injection, aztreonam/avibactam, 7.5 mg/2.5 mg (10 mg)
J0525	Injection, cefotetan disodium, 10 mg
J0582	Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
J1612	Injection, glucagon (gvoke), 0.01 mg
J0668	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
J0675	Injection, carboprost tromethamine, 0.1 mg
J0681	Injection, ceftobiprole medocaril sodium, 3 mg

J0738	Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0752	Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0759	Injection, clevidipine butyrate, 1 mg
J1370	Injection, esomeprazole sodium, 1 mg
J1807	Injection, ethacrynat sodium, 1 mg
J1834	Injection, isoniazid, 1 mg
J2151	Injection, mannitol, 250 mg
J2291	Injection, nafcillin sodium (baxter), 20 mg
J3290	Injection, tranexamic acid, 5 mg
M0235	Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose
M0236	Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose
M0237	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
M0238	Intravenous infusion, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
Q0235	Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
Q0237	Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
Q4383	Axolotl Graft Ultra, per sq cm
Q4384	Axolotl DualGraft Ultra, per sq cm
Q4385	Apollo FT, per sq cm
Q4386	Acesso TrifACA, per sq cm
Q4387	NeoThelium FT, per sq cm
Q4388	NeoThelium 4L, per sq cm
Q4389	NeoThelium 4L Plus, per sq cm
Q4390	Ascension, per sq cm
Q4391	AmnioPlast Double, per sq cm
Q4392	GRAFIX Duo, per sq cm

Q4393	SurGraft AC, per sq cm
Q4394	SurGraft ACA, per sq cm
Q4395	Acelagraft, per sq cm
Q4396	Natalin, per sq cm
Q4397	Summit AAA, per sq cm
0588U	Infectious disease (bacterial or viral), 32 genes (29 informative and 3 housekeeping), immune response mRNA, gene expression profiling by split-well multiplex reverse transcription loop-mediated isothermal amplification (RT-LAMP), whole blood, reported as continuous risk scores for likelihood of bacterial and viral infection and likelihood of severe illness within the next 7 days
0590U	Infectious disease (bacterial and fungal), DNA of 44 organisms (34 bacteria, 10 fungi), urine, next-generation sequencing, reported as positive or negative for each organism
0593U	Infectious disease (genitourinary pathogens), DNA, 46 targets (28 pathogens, 18 resistance genes), RT-PCR amplified probe technique, urine, each analyte reported as detected or not detected
0595U	Infectious disease (tropical fever pathogens), vector-borne and zoonotic pathogens, including 2 viruses (Chikungunya virus and Dengue virus serotypes 1, 2, 3, and 4), 1 bacterium (Leptospira species), and 1 parasite with species differentiation (Plasmodium species, Plasmodium falciparum, and Plasmodium vivax/ovale), real-time RT-PCR, whole blood, each pathogen reported as detected or not detected

**As a reminder, coverage of APAD and APEC carve-out drugs will be redirected to MassHealth for MGB ACO Plans:**

J3403	Revakinagene taroretcel-lwey, per implant
-------	---

**Not covered under medical benefit, coverage redirected under pharmacy benefit for MGB ACO Plans:**

J7173	Injection, concizumab-mtc1, 0.5 mg
J0752	Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)

**Not covered under medical benefit, coverage redirected under pharmacy benefit for Commercial and ASO Plans:**

J0752	Oral, lenacapavir, 300 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
-------	---

**New to Market not covered unless prior authorized for MGB ACO Plans:**

Q5156	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
J0458	Injection, aztreonam/avibactam, 7.5 mg/2.5 mg (10 mg)
C9306	Injection, telisotuzumab vedotin-tllv, 1 mg
Q5158	Injection, denosumab-bnht (bomynta/conexxence), biosimilar, 1 mg
Q5154	Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
Q5159	Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg
Q5157	Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
J0738	Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
J0681	Injection, ceftobiprole medocaril sodium, 3 mg
J7174	Injection, fitusiran, 0.04 mg

**New to Market not covered unless prior authorized for Commercial and ASO Plans:**

Q5156	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
Q5158	Injection, denosumab-bnht (bomynta/conexxence), biosimilar, 1 mg
C9305	Injection, nipocalimab-aahu, 3 mg
Q5154	Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
Q5159	Injection, denosumab-dssb (ospomiy/xbryk), biosimilar, 1 mg
Q5157	Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
Q5155	Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg

**New to Market not covered unless prior authorized for Medicare Advantage Plans:**

Q5156	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
Q5154	Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg